The present invention is directed to a method of producing a Streptococcus thermophilus strain comprising the steps of a) Providing a mother strain in the form of Streptococcus thermophilus DSM32502, b) Growing a culture of the mother strain in the presence of a bacteriophage, to which the mother strain is not resistant, to obtain a number of mutant strains, which are resistant to the said bacteriophage, c) Measuring the acidification time of the bacteriophage-resistant mutant strains and the mother strain in a milk base and selecting at least one mutant strain with a reduced acidification time as compared to the mother strain to obtain a fast-acidifying mutant strain.

Disclosed herein are methods, compositions, kits, and systems for rapid multiplex detection of a microorganism of interest. Recombinant bacteriophages encoding capture moiety-indicator protein fusion products allow for the capture of indicator proteins on a surface. Cocktail compositions of recombinant bacteriophages can be used to detect potentially harmful bacteria. The specificity of recombinant bacteriophages for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

The present invention is directed to a method of producing a Streptococcus thermophilus strain comprising the steps of a) Providing a mother strain in the form of Streptococcus thermophilus DSM32502, b) Growing a culture of the mother strain in the presence of a bacteriophage, to which the mother strain is not resistant, to obtain a number of mutant strains, which are resistant to the said bacteriophage, c) Measuring the acidification time of the bacteriophage-resistant mutant strains and the mother strain in a milk base and selecting at least one mutant strain with a reduced acidification time as compared to the mother strain to obtain a fast-acidifying mutant strain.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.

The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.

Bacteriophage are provided, and methods of making and using the bacteriophage also are provided.

A bacteriophage structure, a method of making the structure, and uses of the structure are described. The structure is a substrate with a surface having an ordered arrangement of parallel microridges thereon. Each microridge is composed of a plurality of nanoridges and has a longitudinal axis. Each nanoridge contains a bundle of phage nano fibers having longitudinal axes. The phage nanofibers in each nanoridge bundle are arranged in a substantially smectic alignment. The longitudinal axis of each microridge is perpendicular to the longitudinal axes of the phage nanofibers which make up the nanoridges of the microridge. The structure may be used as a growth surface for inducing differentiation of stem cells such as neural progenitor cells.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.

Disclosed herein is a particle delivery system comprising electrospun nanofiber comprised of coaxial fiber with a microfluidic core. Iron-doped apatite nanoparticles (IDANPs) have demonstrated a unique influence over phage killing of bacteria, whereby, IDANP-exposed bacterial cultures experience 2× the bacterial death as controls. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the Food and Drug Administration (FDA) for many applications in medicine and dentistry. Previous work has shown that for IDANPs to enhance antibacterial activity of phage to the greatest extent, bacterial cultures should be exposed to IDANPs for 1 hr prior to phage introduction. Biocompatible polymer materials which encase IDANPs and/or phage can be used to disseminate IDANPs and/or phage in a controlled manner into a physiological system for treatment of bacterial infection. When components of said materials contain micro- or nano-scale components, high surface-to-volume ratio for treatment delivery is garnered.

The invention relates to a bactericide composition based on bacteriophages for the control of black plague in plants or parts thereof, preferably walnuts, a preparation method and application. The invention provides methods for the isolation, propagation and application of bacteriophages against phytopathogens affecting trees/plants that are of commercial interest for their fruit, flowers etc., for the prevention, treatment or reduction of signs, in particular, for Xanthomonas A. pv juglandis in walnuts.